Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-08-16 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
对全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's capital increase investment into its wholly-owned subsidiary. It details the amount of capital increase, the purpose, the approval by the board, and financial data of the subsidiary. The document is short (1599 characters) and focuses on a financing activity related to capital injection into a subsidiary. It is not a full financial report, audit report, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it provides an update on the company's financing activity (capital increase in a subsidiary).
2023-08-16 Chinese
关于使用闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of idle raised funds to purchase financial products. It details the background of the fundraising, the usage and storage of the funds, the decision-making process, risk control measures, and opinions from independent directors, the supervisory board, and the sponsoring institution. It does not contain financial statements or detailed financial performance data. The document is relatively short (3183 characters) and serves as a disclosure about capital usage rather than a financial report or earnings release. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including the use of raised funds.
2023-08-16 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 3rd Board of Directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results on various proposals. The document references other filings for detailed reports and announcements but itself is a summary of board decisions. It does not contain financial statements or detailed financial data but rather governance and management decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2023-08-16 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "内蒙古大唐药业股份有限公司2023 年半年度报告" which translates to "Inner Mongolia Grand Pharmaceutical Co., Ltd. 2023 Semi-Annual Report." It contains detailed financial data, including profit and loss statements, balance sheet items, cash flow analysis, business overview, and operational highlights for the period January 1, 2023 to June 30, 2023. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It explicitly states it is a "半年度报告" (semi-annual report), which corresponds to an Interim / Quarterly Report. The content includes comprehensive financial statements and analysis, consistent with the definition of an Interim / Quarterly Report (IR). Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-16 Chinese
独立董事关于第三届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including the use of raised funds, stock repurchase related to an equity incentive plan, and the purchase of financial products with idle raised funds. It references the third board meeting of the third session held on August 15, 2023, and discusses compliance with relevant laws and company rules. The document is a formal opinion related to board decisions rather than a full financial report or earnings release. It does not contain financial statements or detailed financial data but rather governance and compliance opinions on specific corporate actions. This fits best under Board/Management Information (MANG), which covers announcements of board decisions and management-related information.
2023-08-16 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2020年第一期股权激励计划部分限制性股票回购注销之法律意见书
Regulatory Filings
2023-08-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.